Neuromodulators, dermal fillers, biostimulators, and the longevity question. Label-first, comparison-shaped.
Relfydess is the first ready-to-use liquid neuromodulator. A second FDA complete response letter (July 2026) delays US approval. Phase 3 data show day-1 onset and up to…
TrenibotE is the first serotype E neurotoxin submitted for FDA approval. Onset in 8 hours, duration of 2–3 weeks, over 2,100 patients studied. April 2026 CRL addresses…
20 original PMA approvals since 1981, 1,036 total PMA records, and a recent wave of new entrants: what the FDA premarket-approval database reveals about who makes the…
Botox Cosmetic is FDA-approved for platysma bands. Phase III data, FDA dosing (26–36 units), candidacy, Nefertiti lift differences, cost, and realistic results for neck…
98,626 FAERS reports for aesthetic injectables: Botox accounts for 77% of events, Daxxify has the highest serious-event rate at 88%, and top reactions differ sharply…
Counterfeit botulinum toxin has hospitalized patients across the US. How fake injectables enter the supply chain, how to spot them, and what to verify before treatment.
Cross-linking, G-prime, particle size, and manufacturing method determine whether a filler lifts, spreads, or hydrates. Here is the science behind what is actually in…
Most aesthetic injectables are used off-label. What off-label means, where the legal and clinical boundaries lie, and what informed consent requires.
Most filler side effects are mild, but vascular occlusion, infection, and late-onset nodules are real risks. Warning signs, timelines, and what patients should do at…
Travelling to Hong Kong for filler injections adds documentation gaps, follow-up complications, and jurisdictional risks. The GN-00 update helps if you know what to ask…